Myriad Genetics Inc Total Assets
Myriad Genetics Inc total assets. Based on the latest financial reports, Myriad Genetics Inc (MYGN) holds total assets worth $638.90 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of Myriad Genetics Inc for the company's overall valuation and market capitalisation.
Total Assets of Myriad Genetics Inc (1995–2025)
Total assets of Myriad Genetics Inc from 1995 to 2025. This chart illustrates how Myriad Genetics Inc's total assets have evolved over time, based on quarterly financial data. See MYGN stock price and chart for real-time trading data and today's change.
Myriad Genetics Inc - Asset Composition Analysis
Myriad Genetics Inc Total Assets Breakdown (December 2025)
Myriad Genetics Inc total assets breakdown as of December 2025. Myriad Genetics Inc's total assets of $638.90 Million consist of 47.1% current assets and 52.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 21.2% |
| Accounts Receivable | $115.30 Million | 16.3% |
| Inventory | $30.60 Million | 4.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $153.40 Million | 21.7% |
| Goodwill | $51.60 Million | 7.3% |
Asset Composition Trend (1995–2025)
This chart illustrates how Myriad Genetics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Myriad Genetics Inc (MYGN) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Myriad Genetics Inc's current assets represent 47.1% of total assets in 2025, a decrease from 63.6% in 1995.
- Cash Position: Cash and equivalents constituted 21.2% of total assets in 2025, up from 16.6% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 28.0% of total assets, an increase from 0.0% in 1995.
- Asset Diversification: The largest asset category is intangible assets at 21.7% of total assets.
Myriad Genetics Inc Competitors by Total Assets
Key competitors of Myriad Genetics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY
|
USA | $12.00 Billion |
|
Diagnósticos da América S.A
SA:DASA3
|
Brazil | R$21.10 Billion |
|
SMO ClinPlus Co. Ltd.
SHE:301257
|
China | CN¥1.52 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$512.35 Million |
|
RHYTHM Biosciences Ltd
AU:RHY
|
Australia | AU$3.10 Million |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$7.66 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$16.78 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
Myriad Genetics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.21 | 1.42 | 2.46 |
| Quick Ratio | 1.98 | 1.28 | 2.36 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $158.30 Million | $84.40 Million | $295.70 Million |
Myriad Genetics Inc - Advanced Valuation Insights
This section examines the relationship between Myriad Genetics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.00 |
| Latest Market Cap to Assets Ratio | 0.45 |
| Asset Growth Rate (YoY) | -31.2% |
| Total Assets | $706.60 Million |
| Market Capitalization | $321.38 Million USD |
Valuation Analysis
Below Book Valuation: The market values Myriad Genetics Inc's assets below their book value (0.45x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Myriad Genetics Inc's assets decreased by 31.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Myriad Genetics Inc (1995–2025)
The table below shows the annual total assets of Myriad Genetics Inc from 1995 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $706.60 Million | -31.24% |
| 2024-12-31 | $1.03 Billion | -10.37% |
| 2023-12-31 | $1.15 Billion | -4.35% |
| 2022-12-31 | $1.20 Billion | -9.24% |
| 2021-12-31 | $1.32 Billion | -6.91% |
| 2020-12-31 | $1.42 Billion | -9.21% |
| 2019-12-31 | $1.56 Billion | +32.96% |
| 2018-12-31 | $1.18 Billion | -2.78% |
| 2017-12-31 | $1.21 Billion | +37.30% |
| 2016-12-31 | $880.50 Million | +14.92% |
| 2015-12-31 | $766.20 Million | -6.99% |
| 2014-12-31 | $823.80 Million | +2.49% |
| 2013-12-31 | $803.82 Million | +16.39% |
| 2012-12-31 | $690.63 Million | +13.07% |
| 2011-12-31 | $610.83 Million | +2.86% |
| 2010-12-31 | $593.85 Million | +27.33% |
| 2009-12-31 | $466.39 Million | -6.60% |
| 2008-12-31 | $499.34 Million | +32.97% |
| 2007-12-31 | $375.54 Million | +35.77% |
| 2006-12-31 | $276.60 Million | +74.01% |
| 2005-12-31 | $158.96 Million | -15.61% |
| 2004-12-31 | $188.36 Million | +3.03% |
| 2003-12-31 | $182.82 Million | +16.16% |
| 2002-12-31 | $157.39 Million | -8.57% |
| 2001-12-31 | $172.15 Million | +61.83% |
| 2000-12-31 | $106.38 Million | +98.46% |
| 1999-12-31 | $53.60 Million | -20.47% |
| 1998-12-31 | $67.40 Million | -11.43% |
| 1997-12-31 | $76.10 Million | -4.40% |
| 1995-12-31 | $79.60 Million | -- |
About Myriad Genetics Inc
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovar… Read more